Recent Updates
Recently added Catalysts
ABUS

Arbutus to Participate in Upcoming Investor Conferences

Key Takeaway: VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in the following inves

Full Press Release Details

VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in the following investor conferences.
Jefferies 2016 Healthcare Conference, June 7-10, 2016, New York
JMP Securities Healthcare Conference, June 21-22, 2016, New York
A simultaneous webcast of the presentation at Jefferies can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations. Replays will be available on the Arbutus website following the event.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.

Tags

Last updated: Jun 3, 2016